Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada

DENVER, CO / ACCESSWIRE / October 1, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, and Lupin Pharma Canada Ltd ("Lupin"), a subsidiary of global pharma major Lupin Limited, today announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT® and Cotempla XR-ODT® product lines in Canada.

Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder ("ADHD") in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. Cotempla XR-ODT is the only extended-release orally disintegrating tablet methylphenidate and is FDA-approved as a once-daily ADHD treatment for patients 6 to 17 years of age.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
1057 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2552Followers
    107Following
    28KVisitors
    Follow